Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Mechanisms of mRNA Translation in Pancreatic Cancer
share announcement

Mechanisms of mRNA Translation in Pancreatic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 15 December 2024 | Viewed by 1155

Special Issue Editor

Dr. Kamini Singh

E-Mail Website
Guest Editor
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA
Interests: cancer biology; cancer initiation and maintenance; oncogene function; mechanisms of mRNA translation; mechanisms of translation start site selection; mRNA translation in cancer; KRAS-driven mRNA translation; KRAS signaling; regulation of KRAS protein production; pancreatic cancer; cancer genomics; cancer therapeutics; cancer immunotherapy; RNA binding proteins; targeting mRNA translation; EIF4A inhibitors; MYC-driven mRNA translation; translation initiation factors; translation elongation factors; ribosome footprinting; single cell ribosome footprinting; ribosome stalling; nascent proteome in cancer; neoantigens in cancer; mRNA translation in tumor microenvironment; mRNA translation in T cells

Special Issue Information

Dear Colleagues,

We are seeking original research articles that explore the mechanistic aspects of mRNA translation control and its impact on the development and progression of pancreatic cancer. Specifically, we encourage studies that investigate the role of aberrant translation regulation in oncogenesis and the overexpression of oncogenic proteins in pancreatic cancer cells. We also welcome studies that elucidate the signaling pathways and molecular mechanisms involved in mRNA translation regulation and the effects of changes in the tumor microenvironment on translation in pancreatic cancer. Additionally, we are interested in studies that focus on developing novel therapeutic strategies for pancreatic cancer by targeting the translation machinery, such as inhibiting the activity of translation initiation factors or targeting specific mRNAs overexpressed in pancreatic cancer cells. The scope of this Special Issue is broadly on the mechanisms of mRNA translation in pancreatic cancer, and it involves a range of disciplines and techniques, including molecular biology, biochemistry, cancer cell biology, and therapeutics.

Dr. Kamini Singh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer biology
  • mechanisms of mRNA translation
  • cancer therapeutics
  • RNA binding proteins
  • targeting mRNA translation
  • translation initiation factors
  • translation elongation factors
  • ribosome footprinting
  • single-cell ribosome footprinting
  • mRNA translation in tumor microenvironment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 3216 KiB  
Article
Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining
by Sung Ill Jang, Ji Hae Nahm, See Young Lee, Jae Hee Cho, Min-Young Do, Joon Seong Park, Hye Sun Lee, Juyeon Yang, Jiwon Kong, Seunghwan Jung, Sunghoon Kim and Dong Ki Lee
Cancers 2023, 15(22), 5413; https://doi.org/10.3390/cancers15225413 - 14 Nov 2023
Viewed by 827
Abstract
The serum level of CA 19-9 is a prognostic marker for pancreatic ductal adenocarcinoma (PDAC). We evaluated the ability of the expression level of methionyl-tRNA synthetase 1 (MARS1)—which facilitates cancer growth by modulating protein synthesis and the cell cycle—to predict the prognosis of [...] Read more.
The serum level of CA 19-9 is a prognostic marker for pancreatic ductal adenocarcinoma (PDAC). We evaluated the ability of the expression level of methionyl-tRNA synthetase 1 (MARS1)—which facilitates cancer growth by modulating protein synthesis and the cell cycle—to predict the prognosis of PDAC. Immunohistochemical (IHC) staining was performed on pancreatic specimens obtained from patients with PDAC who were undergoing surgery. High MARS1 expression was defined as equal to, or greater than, that in normal acinar cells. Low MARS1 expression was defined as weaker than in normal acinar cells, and stronger than in the pancreatic duct epithelium. Univariate and multivariate analyses were performed on other factors related to prognosis. Among 137 PDAC patients, no significant differences in baseline characteristics were found between those with high (n = 82) and low (n = 55) MARS1 expression. The median overall survival time of patients with high MARS1 expression was shorter than that of those with low expression (15.2 versus 17.2 months, log-rank test p = 0.044). The median disease-free survival (DFS) was not significantly different between the two groups. However, the DFS was shorter in patients with high than in those with low MARS1 expression (8.9 versus 11.2 months, log-rank test p = 0.067). In a multivariate analysis, lymph node metastasis and high MARS1 expression were associated with a poor prognosis of PDAC. Elevated MARS1 expression detected by IHC staining is associated with a poor prognosis of PDAC, suggesting that MARS1 has potential as a prognostic marker. Full article
(This article belongs to the Special Issue Mechanisms of mRNA Translation in Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop